Sharekhan is bullish on Strides Pharma Sciences has recommended buy rating on the stock with a target price of Rs 450 in its research report dated January 25, 2023.

The US FDA’s EIR is received for the drug-device combination to be commercialised from the Stelis Pharma's flagship facility in Bengaluru, India

Strides Pharma's step-down subsidiary in Singapore received AUD 94 million or Rs 525 crore as the deferred consideration for the sale of the Company’s Australian operations in 2019. The proceeds will be utilized for deleveraging the balance sheet, the firm said in an exchange filing.

Hindustan Copper has broken out from the downward sloping trend line on its weekly charts. Volumes have been gradually rising along with the price rise.

Sharekhan is bullish on Strides Pharma Sciences has recommended buy rating on the stock with a target price of Rs 450 in its research report dated November 15, 2022.

The approval granted by the US Food & Drug Administration (USFDA) to Strides Pharma Global Pte Ltd, Singapore, is for potassium chloride oral solution of strength 40 mEq/15mL (20 per cent), Strides Pharma Science (Strides) said in a regulatory filing.

Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 3085.64 Crore) operating in Pharmaceuticals sector.

The USFDA noted in its report that the company, a subsidiary of Mumbai-based drug firm, is recalling the affected lot due to "blister package issues." The lot was produced at Glenmark's Pithampur (Madhya Pradesh) based manufacturing facility. The USFDA stated that Glenmark initiated the Class II nationwide (US) recall on June 29 this year.

Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 3026.83 Crore) operating in Pharmaceuticals sector.

Sharekhan is bullish on Strides Pharma Sciences has recommended buy rating on the stock with a target price of Rs 450 in its research report dated July 29, 2022.

The company had posted a consolidated net loss at Rs 244.1 crore in the same quarter previous fiscal, Strides Pharma Science Ltd said in a regulatory filing.

Revenue from the US business in the June quarter stood at Rs 355.2 crore, up from Rs 301.6 crore last year.Similarly, the company said its revenues from Other Regulated Markets (ORM) was at Rs 304.7 crore in the first quarter of FY23. The same stood at Rs 223.2 crore in the corresponding period last fiscal

Most sectors, barring IT, participated in the rally on June 24. Bank, auto, financial services, FMCG, and metal indices gained 1.2-2 percent

The vaccine was well tolerated with no significant safety concerns and a seroconversion rate of 91%

The Nifty Pharma index was trading 0.46 per cent up at 12182.65.

Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 2836.92 Crore) operating in Pharmaceuticals sector.

Geojit recommended accumulate rating on Strides Pharma Science with a target price of Rs 355 in its research report dated June 23, 2022.

The Nifty Pharma index was trading 1.69 per cent down at 11863.0.

Strides Pharma Science and Indraprastha Gas, which were among the top gainers in the F&O segment, and Affle formed bullish candlesticks on the daily chart on June 15

​​​ As per the latest enforcement report by the US Food and Drug Administration (USFDA), the company, which is a unit of Bengaluru-headquartered Strides Pharma Science, is recalling 6,78,829 bottles of the blood pressure lowering drug in the US market.

The Nifty Pharma index closed 3.69 per cent up at 13065.5.

In the letter written on May 13, Arun Kumar, Founder and Director of Stelis Biopharma Limited, said that after the prime minister had requested the industry to gear up to tackle the pandemic, the firm invested over Rs 700 crore to set up a state-of the-art vaccine manufacturing facility within six months despite the COVID-19-induced restrictions and quickly commenced the production of Sputnik Light.